Digitizing cancer rehabilitation for patients during and after treatment
Digitizing Cancer Rehabilitation During and After Systemic Treatment: Feasibility Testing Implementation in South Baltic Countries
This study is testing a new online rehab program for cancer patients to see if it can help them feel better and get back to their daily lives during and after treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Zealand University Hospital Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 5 sites (Næstved and 4 other locations) |
| Trial ID | NCT06768918 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the feasibility of implementing digitally supported rehabilitation for cancer patients during and after systemic treatment. It focuses on remote physical rehabilitation to improve quality of life, functional ability, and participation in everyday life. The study addresses barriers such as distance to rehabilitation facilities and heavy treatment schedules that may hinder patient participation. By utilizing telehealth, the research seeks to enhance accessibility to rehabilitation services for cancer survivors, particularly in rural areas.
Who should consider this trial
Good fit: Ideal candidates include cancer patients undergoing systemic treatment or those who have recently completed chemotherapy.
Not a fit: Patients who are cognitively unable to consent to or participate in a digital rehabilitation program will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve access to rehabilitation services for cancer patients, enhancing their recovery and quality of life.
How similar studies have performed: Other studies have shown promise in utilizing telehealth for rehabilitation, indicating potential success for this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed with cancer (IDC: C00\* - C97\*) * Feasibility study 1 (early rehab): Participants should receive any systemic chemo/immunotherapy preferably (but not necessarily) with a duration of 8 weeks or more. Recruitment should be at earliest convenience preferably (but not necessarily) within 4 weeks of treatment initiation. * Feasibility study 2 (rehab@home): Participants should preferably have completed chemotherapy/immunotherapy no more than 6 months ago but may be receiving long-standing maintenance and life-prolonging chemo-/immunotherapy. Exclusion Criteria: \- Cognitively unable to give consent to, or participate in, a digital rehabilitation programme as judged by project team staff.
Where this trial is running
Næstved and 4 other locations
- Zealand Unievrsity Hospital — Næstved, Denmark (Recruiting)
- University Medical Center Rostock — Rostock, Germany (Recruiting)
- Klaipeda University — Klaipėda, Lithuania (Recruiting)
- Medical University of Gdansk — Gdansk, Poland (Recruiting)
- Ängelholm Hospital — Ängelholm, Sweden (Recruiting)
Study contacts
- Principal investigator: Susanne O Dalton, MD PhD — Zealand University Hospital, Department of Clinical Oncology and Palliative Care
- Study coordinator: Gunn Ammitzbøll, PhD
- Email: gai@regionsjaelland.dk
- Phone: + 45 22 46 27 33
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.